Effect of an alpha-glucosidase inhibitor combined with sulphonylurea treatment on glucose metabolism in patients with non-insulin-dependent diabetes mellitus
Okada, S.; Ishii, K.; Tanokuchi, S.; Hamada, H.; Ichiki, K.; Ota, Z.
Journal of International Medical Research 23(4): 279-283
1995
ISSN/ISBN: 0300-0605 PMID: 7589771 Document Number: 447031
Ten patients with non-insulin-dependent diabetes mellitus who were being treated with a sulphonylureal compound but whose glucose metabolism needed further improvement were given a combination of their usual sulphonylurea treatment and an alpha-glucosidase inhibitor. Treatment with the alpha-glucosidase inhibitor (0.6 mg/day), in addition to glibenclamide (7.5 mg/day in two patients; 5.0 mg/day in four; 2.5 mg/day in one) or tolbutamide (500 mg/day in three patients) for 4 weeks, improved hyperglycemia after meals from 237 - 247 mg/dl to 192 mg/dl, and reduced glycosylated haemoglobin levels from 8.5 - 8.6% to 7.9% without causing hypoglycemia.